Clinical trial NCT00796939: Effects of Light Treatment During Sleep on Young Men
Official title: Randomized, Placebo-Controlled Trial of Short Wavelength Light Administered Just Prior to Waking in Young Men
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Depression
Keywords: Delayed Sleep Phase Syndrome
Sleep
Lead sponsor: University of California, San Diego
Sponsor class: OTHER
Collaborators: name: National Institute of Mental Health (NIMH)
First posted: 2008-11-24
Enrollment: 30
Sex: MALE
Minimum age (years): 25
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study will determine if green light exposure during sleep is effective in reducing mild depression symptoms in young men.

Detailed description: The circadian rhythm is the human body's internal clock. It affects sleeping and wakefulness patterns. Some scientists theorize that a disruption of circadian rhythms, or other circadian abnormalities, can cause a depressed state. Light received through the eyes can alter the circadian rhythm, and sustained exposure to artificial bright light during the last half of usual sleep time can change the phase of the circadian rhythm. Several studies have found that exposure to bright white light in the morning hours is an effective treatment for depression, especially during the first week of depression treatment. Other studies have shown that green or blue light is preferable to yellow or red light in depression treatment. This study will expose young men to different types of light during the last part of their sleep cycle to determine whether the treatment is safe and tolerable and whether it reduces mood disturbance and depression. The study will also determine the light's effect on the production of luteinizing hormone (LH) and testosterone, hormones that may play a role in depression.

Participation in this study will last 15 days. At the beginning of the study, participants will be provided with study materials and instructed in their use. These materials will include a wrist actigraph, which is a sleep and wakefulness monitoring device similar to a wristwatch; a binder containing instructions, questionnaires, and forms; and a light mask. Participants will be randomly assigned to receive a light mask with either intense green or dim red light. Participants will wear the wrist actigraph throughout the study. For the first 3 days of the study, participants will sleep normally and fill out questionnaires and a sleep diary. The questionnaires will measure mood, sleepiness, sleep quality, treatment effects, and sleep time preference. The sleep diary will be a record of time spent sleeping, time it takes to fall asleep, number of times waking during the night, and similar measures. Starting on the third night, participants will wear the light mask when sleeping. Every day participants will fill out the questionnaires and sleep diary, and they will contact the study investigators to ensure compliance and to ask any questions. Participants will also provide saliva and urine samples once at the beginning and once at the end of the study. These samples will be used to test for testosterone and LH, respectively.

Eligibility criteria: Exclusion Criteria:

* Presence of clinical depression
* Presence of a sleep disorder

Primary outcomes:
measure: Safety, measured through the Systematic Assessment for Treatment Emergent Effects (SAFTEE) questionnaire
timeFrame: Measured on Days 3 and 15
measure: Tolerability, measured through compliance reports
timeFrame: Measured daily for the length of the study
measure: Mood disturbance, measured on the Quick Inventory of Depressive Symptomology-Self Report (QIDS-SR)
timeFrame: Measured on Days 3 and 15
Secondary outcomes:
measure: Sleep diary
timeFrame: Measured daily for the duration of the study
measure: Mood visual analog scale
timeFrame: Measured daily for the duration of the study
measure: Luteinizing hormone, measured through urinalysis
timeFrame: Measured on Days 3 and 13
measure: Testosterone, measured through saliva analysis
timeFrame: Measured on Days 3 and 13
Other outcomes:
Locations:
city: La Jolla
country: United States
facility: UCSD
state: California
Study officials:
References: